Etanercept in Alzheimer disease

Neurology

Volumn 84, Issue 21, 2015, Pages 2161-2168

  Butchart, Joseph ^a,c   Brook, Laura ^a,c   Hopkins, Vivienne ^c   Teeling, Jessica ^b   Püntener, Ursula ^b   Culliford, David ^a   Sharples, Richard ^c   Sharif, Saif ^c   McFarlane, Brady ^d   Raybould, Rachel ^f   Thomas, Rhodri ^f   Passmore, Peter ^e   Perry, V Hugh ^b   Holmes, Clive ^a,c  

^a Dermatology Department   (United States)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c MOORGREEN HOSPITAL   (United Kingdom)

^d Becton Health Centre Southern Health Foundation Trust   (United Kingdom)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATININE; DNA ANTIBODY; ETANERCEPT; PLACEBO; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

AGED; ALZHEIMER DISEASE; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ANTIBODY BLOOD LEVEL; ARTICLE; ATRIAL FIBRILLATION; BACKACHE; BALANCE DISORDER; CELLULITIS; CERUMEN IMPACTION; CLINICAL ARTICLE; COLON POLYP; COLONOSCOPY; CONFUSION; CONSTIPATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEHYDRATION; DELUSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECZEMA; EPIGASTRIC DISCOMFORT; EYE PAIN; FATIGUE; FEMALE; GASTROENTERITIS; HALLUCINATION; HEADACHE; HEARING IMPAIRMENT; HEART RATE; HEART SOUND; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; INJECTION SITE REACTION; JOINT STIFFNESS; KERATITIS; LYMPHEDEMA; MALE; MALIGNANT NEOPLASTIC DISEASE; MUSCLE WEAKNESS; NAUSEA AND VOMITING; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PARKINSONISM; PAROSMIA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOMETRY; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; RESPIRATORY TRACT INFECTION; SCIATICA; SEBORRHEIC DERMATITIS; SEBORRHEIC KERATITIS; SIDE EFFECT; SPINE FRACTURE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE INCONTINENCE; VARICOSE ECZEMA; YAWNING; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; ETANERCEPT; FEMALE; HUMANS; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929937549     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000001617     Document Type: Article

References (33)

1. Perry VH, Cunningham C, Holmes C. Systemic infections and inflammation affect chronic neurodegeneration. Nat Rev Immunol 2007;7:161-167.
2. Drake C, Boutin H, Jones MS, et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain Behav Immun 2011;25:1113-1122.
3. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci 2005;25:9275-9284.
4. Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009;73:768-774.
5. Holmes C, Cunningham C, Zotova E, Culliford D, Perry VH. Proinflammatory cytokines, sickness behavior, and Alzheimer disease. Neurology 2011;77: 212-218.
6. Tobinick E, Gross H, Weinberger A, Cohen H. TNFalpha modulation for treatment of Alzheimer's disease: a 6-month pilot study. MedGenMed 2006;8:25.
7. Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer's disease following perispinal etanercept administration. J Neuroinflammation 2008;5:2.
8. Tobinick EL, Gross H. Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer's disease. BMC Neurol 2008;8:27.
9. Tobinick EL, Chen K, Chen X. Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes 2009;2:28.
10. Perry VH, Holmes C. Microglial priming in neurodegenerative disease. Nat Rev Neurol 2014;10:217-224.
11. McKhann G, Drachman D, FolsteinM, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
12. Lim A, Tsuang D, Kukull W, et al. Clinico-neuropathological correlation of Alzheimer's disease in a communitybased series. J Am Geriatr Soc 1999;47:564-569.
13. Holmes C, Cairns N, Lantos P, Mann A. Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. Br J Psychiatry 1999;174:45-50.
14. Hachinski VC, Iliff LD, Zilhka E, et al. Cerebral blood flow in dementia. Arch Neurol 1975;32:632-637.
15. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. Int Psychogeriatr 1997; 9(suppl 1):87-94; discussion 143-150.
16. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356-1364.
17. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing 1996;25:113-120.
18. Guy W. Clinical Global Impressions (CGI) Scale. In: Rush J; American Psychiatric Association. Task Force for the Handbook of Psychiatric Measures. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000.
19. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23:271-284.
20. Cummings JL. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology 1997; 48(5 suppl 6):S10-S16.
21. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006;(1):CD005593.
22. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev 2002;(2):CD003673.
23. Browne RH. On the use of a pilot sample for sample size determination. Stat Med 1995;14:1933-1940.
24. Sim J, Lewis M. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency. J Clin Epidemiol 2012;65:301-308.
25. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287-291.
26. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-805.
27. Summary of product characteristics (ENBREL). Available at: http://www.medicines.org.uk/emc/medicine/3343/SPC/Enbrel1251mg1powder1and1solvent1for1solution 1for1injection/. Accessed January 29, 2015.
28. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev 2010;(8):CD007514.
29. Howard R, Phillips P, Johnson T, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011;26:812-817.
30. Schulz M, Dotzlaw H, Neeck G. Ankylosing spondylitis and rheumatoid arthritis: serum levels of TNF-alpha and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed Res Int 2014;2014: 675108.
31. Madhusudan S, Muthuramalingam SR, Braybrooke JP, et al. Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer. J Clin Oncol 2005; 23:5950-5959.
32. Holmes C, Butchart J. Systemic inflammation and Alzheimer's disease. Biochem Soc Trans 2011;39:898-901.
33. Novella S. Enbrel for Stroke and Alzheimer's: Science Based Medicine. 2014. Available at: http://www. sciencebasedmedicine.org/enbrel-for-stroke-andalzheimers/. Accessed January 29, 2015.